Eli Lilly reported positive Phase 3 results for Foundayo (orforglipron) in a cardiovascular outcomes trial in adults with type 2 diabetes and obesity or overweight. The company said the study met its primary safety objective, demonstrating non-inferiority for major adverse cardiovascular events versus insulin glargine. Lilly also reported statistically significant improvements in blood sugar and body weight compared with insulin at 52 weeks, with effects said to hold through 104 weeks. The company said the trial included 2,749 participants across 15 countries and followed patients for up to two years for CV events. Lilly said it will seek FDA approval in diabetes by the end of the second quarter using a national priority review voucher, potentially extending the oral GLP-1 competition into an additional indication beyond obesity.